EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients

Mahboubeh Fereidan-Esfahani, Paul A Decker, Stephen D Weigand, Alfonso S Lopez Chiriboga iD, Eoin P Flanagan, Jan-Mendelt Tillema, Claudia F Lucchinetti iD, Jeanette E Eckel-Passow, W Oliver Tobin iD

Annals of Clinical and Translational Neurology · 2023-09 · 10 (9) · 1544-1555

DOI: 10.1002/acn3.51844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 13.07.2023. Verfasst von Mahboubeh Fereidan-Esfahani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Multiple Sclerosis, Brain Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe demographic, clinical, and radiographic features of tumefactive demyelination (TD) and identify factors associated with severe attacks and poor outcomes.

Methods

Retrospective review of TD cases seen at Mayo Clinic, 1990–2021.

Results

Of 257 patients with TD, 183/257 (71%) fulfilled the 2017 multiple sclerosis (MS) McDonald criteria at the last follow‐up, 12/257 (5%) had myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), 0 had aquaporin‐4‐IgG seropositive neuromyelitis optic spectrum disorders (AQP4+ NMOSD), and 62/257 (24%) were cryptogenic. Onset before age 18 was present in 18/257 (7%). Female to male ratio was 1.3:1. Cerebrospinal fluid oligoclonal (CSF) bands were present in 95/153 (62%). TD was the first demyelinating attack in 176/257 (69%). At presentation, 59/126 (47%) fulfilled Barkhof criteria for dissemination in space, 59/100 (59%) had apparent diffusion coefficient (ADC) restriction, and 57/126 (45%) had mass effect. Despite aggressive clinical presentation at onset, 181/257 (70%) of patients remained fully ambulatory (Expanded Disability Status Scale [EDSS] ≤4) after a 3.0‐year median follow‐up duration. Severe initial attack‐related disability (EDSS ≥4) was more common in patients with motor symptoms (81/143 vs. 35/106, p < 0.0001), encephalopathy (20/143 vs. 2/106, p < 0.0001) and ADC restriction on initial MRI (42/63 vs. 15/33, p = 0.04). Poor long‐term outcome (EDSS ≥4) was more common in patients with older onset age (41.9 ± 15 vs. 36.8 ± 15.6, p = 0.02) and motor symptoms at onset (49/76 vs. 66/171, p < 0.0001).

Interpretation

Most TD patients should be considered part of the MS spectrum after excluding MOGAD and NMOSD. Motor symptoms and older age at presentation portend a poor outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaMultiple SclerosisBrain DiseasesMaleFemaleHumansRetrospective StudiesAquaporin 4

Substanzen

Aquaporin 4

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Dell Medical School, University of Texas, Austin, Texas, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Laboratory Medicine and Pathology, Minneapolis, Minnesota, USA.

ORCID-Profile: Alfonso S Lopez Chiriboga, Claudia F Lucchinetti, W Oliver Tobin

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Fereidan-Esfahani, M., Decker, P. A., Weigand, S. D., Lopez Chiriboga, A. S., Flanagan, E. P., Tillema, J. M., Lucchinetti, C. F., Eckel-Passow, J. E., & Tobin, W. O. (2023). Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Annals of Clinical and Translational Neurology, 10(9), 1544-1555. https://doi.org/10.1002/acn3.51844

Vancouver

Fereidan-Esfahani M, Decker PA, Weigand SD, Lopez Chiriboga AS, Flanagan EP, Tillema JM, et al. Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Annals of Clinical and Translational Neurology. 2023;10(9):1544-1555. doi:10.1002/acn3.51844

BibTeX
@article{FereidanEsfahani2023,
  author = {Fereidan-Esfahani, Mahboubeh and Decker, Paul A and Weigand, Stephen D and Lopez Chiriboga, Alfonso S and Flanagan, Eoin P and Tillema, Jan-Mendelt and Lucchinetti, Claudia F and Eckel-Passow, Jeanette E and Tobin, W Oliver},
  title = {Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2023},
  volume = {10},
  number = {9},
  pages = {1544--1555},
  doi = {10.1002/acn3.51844}
}
Kostenlos starten →